Key points are not available for this paper at this time.
“Taken together, the results from this analysis represent a key opportunity to intensify [cardiovascular] kidney therapies in real-world practice in high-risk CKD even without overt [cardiovascular disease] being present, given comparable event rates and benefits from therapies. Implementing thera...”
Rangaswami et al. (Mon,) studied this question.